Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX 470 vs Latanoprost in Glaucoma and Ocular Hypertension
NCT03657797Phase 2Completed
- Sponsor
- Nicox S.A.
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NCX 470 in open-angle glaucoma (OAG) and ocular hypertension (4 arms), sponsored by Nicox S.A. Primary endpoint: Change From Baseline in Study Eye Mean Diurnal Intraocular Pressure at 4 weeks. Started Aug 2018; status: completed.
02
Drugs
NCX 470
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03657797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657797.